Literature DB >> 21910223

FGFR3 related skeletal dysplasias diagnosed prenatally by ultrasonography and molecular analysis: presentation of 17 cases.

Angeliki Hatzaki1, Stavros Sifakis, Despina Apostolopoulou, Dimitra Bouzarelou, Anastasia Konstantinidou, Dimitra Kappou, Apostolos Sideris, Emmanouil Tzortzis, Apostolos Athanassiadis, Lina Florentin, Perikles Theodoropoulos, Constantinos Makatsoris, Charalambos Karadimas, Voula Velissariou.   

Abstract

Fibroblast Growth Factor Receptor 3 (FGFR3) related skeletal dysplasias are caused by mutations in the FGFR3 gene that result in increased activation of the receptors causing alterations in the process of endochondral ossification in all long bones, and include achondroplasia, hypochondroplasia, thanatophoric dysplasia, and SADDAN. Reports of prenatal diagnosis of FGFR3 related skeletal dysplasias are not rare; however, the correlation between 2nd trimester ultrasonographic findings and underlying molecular defect in these cases is relatively poor. There is a need for specific ultrasound (U/S) predictors than can distinguish lethal from non-lethal cases and aid an earlier prenatal diagnosis. Here we present one familial and 16 sporadic cases with FGFR3 related skeletal dysplasia, and we evaluate biometric parameters and U/S findings consistent with the diagnosis of skeletal dysplasia. U/S scan performed even at the 18th week of gestation can indicate a decreased rate of development of the femora (femur length (FL) <5th centile), while the mean gestational age at diagnosis is still around the 26th week. The utility of other biometric parameters and ratios is discussed (foot length, BPD, HC, FL/foot, and FL/AC). Prenatal cytogenetic and molecular genetic analyses were performed. A final diagnosis was reached by molecular analysis. In two cases of discontinued pregnancy, fetal autopsy led to a phenotypic diagnosis and confirmed the prenatal prediction of lethality. We conclude that the combination of U/S and molecular genetic approach is helpful for establishing an accurate diagnosis of FGFR3-related skeletal dysplasias in utero and subsequently for appropriate genetic counselling and perinatal management.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21910223     DOI: 10.1002/ajmg.a.34189

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  6 in total

Review 1.  A system-based approach to the genetic etiologies of non-immune hydrops fetalis.

Authors:  Anne H Mardy; Shilpa P Chetty; Mary E Norton; Teresa N Sparks
Journal:  Prenat Diagn       Date:  2019-06-26       Impact factor: 3.050

Review 2.  Achondroplasia: a comprehensive clinical review.

Authors:  Richard M Pauli
Journal:  Orphanet J Rare Dis       Date:  2019-01-03       Impact factor: 4.123

3.  Molecular Analysis of a Case of Thanatophoric Dysplasia Reveals Two de novo FGFR3 Missense Mutations located in cis.

Authors:  Renate Marquis-Nicholson; Salim Aftimos; Donald R Love
Journal:  Sultan Qaboos Univ Med J       Date:  2013-02-27

4.  Thanatophoric dysplasia in a dichorionic twin confirmed by genetic analysis at the early second trimester: A case report and literature review.

Authors:  Inji Cho; Jae-Yoon Shim; Gu-Hwan Kim; Han-Wook Yoo; Eun Jung Lee; Hye-Sung Won; Pil Ryang Lee; Ahm Kim
Journal:  Obstet Gynecol Sci       Date:  2014-03-15

Review 5.  The Role of Fibroblast Growth Factor (FGF) Signaling in Tissue Repair and Regeneration.

Authors:  Mariya Farooq; Abdul Waheed Khan; Moon Suk Kim; Sangdun Choi
Journal:  Cells       Date:  2021-11-19       Impact factor: 6.600

6.  Successful birth with preimplantation genetic diagnosis using single-cell allele-specific PCR and sequencing in a woman with hypochondroplasia due to FGFR3 mutation (c.1620C>A, p.N540K).

Authors:  Kyung Eui Park; Sung Ah Kim; Moon Joo Kang; Hee Sun Kim; Sung Im Cho; Kyoung Won Yoo; So Yeon Kim; Hye Jun Lee; Sun Kyung Oh; Moon-Woo Seong; Seung-Yup Ku; Jong Kwan Jun; Sung Sup Park; Young Min Choi; Shin Yong Moon
Journal:  Clin Exp Reprod Med       Date:  2013-03-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.